Aerocrine and Panasonic Shikoku Electronics : asthma partnership

4 November 2009 – Aerocrine AB (OMX Nordic Exchange: AERO) announced that Aerocrine and Panasonic Shikoku Electronics, CO., LTD (PSEC) have entered into a long-term agreement to develop, manufacture and market new generation products for airway inflammation monitoring using exhaled nitric oxide.

PSEC, a wholly owned subsidiary of Panasonic Corporation, is a world class electronic development, manufacturing and marketing corporation with extensive experience in designing and manufacturing consumer and professional medical devices. Aerocrine is a clinically based medical technology corporation that discovered exhaled nitric oxide monitoring for clinical use in asthma care and leads the market with proprietary technology and products for airway inflammation measurement.



Under the agreement, Aerocrine and PSEC will collaborate to develop future generations of products for airway inflammation monitoring for both clinical and personal use. PSEC will be responsible for the worldwide manufacture and supply of the products and Aerocrine will be responsible for regulatory approvals, method development and global commercialization... Aerocrine's Press Release -

Aerocrine, NIOX MINO: a New Hand-Held Device to Measure Airway Inflammation in Asthma

4 March, 2008 - NIOX MINO® Set to Dramatically Improve Airway Inflammatory Disease Management through Personalized Inflammation Control.
Aerocrine, Inc. (STO:AEROB) announced that NIOX MINO, a hand-held point-of-care device for the measurement of airway inflammation, has been 510(k) cleared by the U.S. Food and Drug Administration (FDA). Physicians in the U.S. now have a highly accurate, non-invasive and convenient technology that is appropriate for use in a doctor’s office, ultimately helping them improve how they treat asthma patients.NIOX MINO provides accurate, reproducible and immediate measurement of fractional exhaled nitric oxide (FENO), a validated method for assessing asthma-related airway inflammation. NIOX MINO is the first hand-held device to measure airway inflammation—an underlying cause of inflammatory airway diseases—helping physicians improve patient outcomes and reduce healthcare expenditures... [PDF] Aerocrine's Press Release -

Aerocrine, Chest M.I. market and sell NIOX MINO in Japan

February 11, 2008 – Aerocrine AB (OMX Nordic Exchange: AERO) announces that the company has entered into a distribution agreement with Chest M.I. Inc. Chest will market and sell NIOX MINO® in Japan.Chest manufactures and sells a large range of products to measure lung function as well oxygen delivery systems for home use.
The company which was founded in 1965 is one of the largest companies in its field with over 50% share of the Japanese market.Chest has an impeccable reputation and impressive market coverage with over 10 local sales offices. Chest will apply for market authorization of NIOX MINO in Japan and then proceed to product launch... [PDF] Aerocrine's Press Release-